Clearly, the understanding of diversity and heterogeneity detected in immune molecules regulating tumor-host interactions (such as MHC) can represent one of the main challenges to overcome in the future development of immunotherapies for colon cancer. This evidence concerns the gene HLA-C and neoplasm.